Fate Therapeutics’ (FATE) “Hold” Rating Reaffirmed at Needham & Company LLC
Fate Therapeutics (NASDAQ:FATE – Get Free Report)‘s stock had its “hold” rating reissued by analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports. A number of other equities research analysts also recently commented on the stock. Wedbush reaffirmed a “neutral” rating and issued a $5.00 target price on shares of […]
Fate Therapeutics (NASDAQ:FATE – Get Free Report)‘s stock had its “hold” rating reissued by analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports. A number of other equities research analysts also recently commented on the stock. Wedbush reaffirmed a “neutral” rating and issued a $5.00 target price on shares of […]
